SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2013 Customer	Sep. 30, 2012	Mar. 31, 2012 Payment	Sep. 30, 2013 Quarter Customer	Sep. 30, 2012	Dec. 31, 2012
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	$ 5,044,682			$ 5,044,682		$ 5,082,360
Number of customers	2			2
Royalty revenue	3,087,491	2,307,073		9,717,994	6,698,355
Royalty / Mark-up on Cost of Goods Sold / Earn-Out Revenue [Abstract]
Number of quarters after which revenue is recognized (in quarters)				1
Number of days after calendar year, after which payments and report are received				90 days
Number of years for which bad debt expense not recorded				3 years
Allowance for doubtful accounts	30,000	30,000		30,000	30,000
Reimbursable Third Party Development Costs [Abstract]
Accrued patent costs	45,000			45,000
Royalty Buy-Down [Abstract]
Initial payment for royalty buy down			1,500,000	0	1,500,000
Number of additional cash payments for royalty buy down			5
Deferred royalty buy-down	2,750,000			2,750,000		2,750,000
Deferred costs, amortization period				5 years
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Expected volatility rate (in hundredths)				33.00%
Risk free interest rate (in hundredths)				1.73%
Average exercise period				5 years
Stock-based compensation expense	1,172	26,400		106,622	202,085
Total number of shares
Outstanding, beginning of period (in shares)				1,182,000
Granted (in shares)				30,000
Forfeited (in shares)				(15,000)
Exercised (in shares)				(10,000)
Expired (in shares)				0
Outstanding, end of period (in shares)	1,187,000			1,187,000
Exercisable, end of period (in shares)	1,152,000			1,152,000
Weighted-Average Exercise Price
Outstanding, beginning of period (in dollars per share)				$ 8.90
Granted (in dollars per share)				$ 16.88
Forfeited (in dollars per share)				$ 30.79
Exercised (in dollars per share)				$ 1.00
Expired (in dollars per share)				$ 0
Outstanding, end of period (in dollars per share)	$ 8.89			$ 8.89
Exercisable, end of period (in dollars per share)	$ 8.42			$ 8.42
Proceeds from stock option exercises				10,000	148,425
Aggregate intrinsic value of options outstanding and exercisable	8,200,000			8,200,000
Closing price of Company stock (in dollars per share)	$ 19.47			$ 19.47
Unrecognized compensation cost related to non-vested stock options outstanding	77,000			77,000
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of property, plant and equipment				5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of property, plant and equipment				10 years
Director [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock granted during period, value of stock options	78,000
Total number of shares
Granted (in shares)	15,000
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	0	13,200		92,249	158,017
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,172	13,200		14,372	44,068
Auxilium [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	1,500,000			1,500,000
Royalty revenue	2,100,000
Deferred revenue	200,000			200,000
Auxilium [Member] | Accounts Receivable [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)				30.00%
Auxilium [Member] | Licensing, Consulting And Royalty Revenue [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)	68.00%
DFB Biotech Inc. [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Accounts receivable	3,500,000			3,500,000
Royalty revenue	$ 1,000,000
DFB Biotech Inc. [Member] | Accounts Receivable [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)				70.00%
DFB Biotech Inc. [Member] | Licensing, Consulting And Royalty Revenue [Member]
Concentration of Credit Risk and Major Customers [Abstract]
Concentration risk percentage (in hundredths)	32.00%